{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:13:52Z","timestamp":1793610832883,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.09.053","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T08:37:56Z","timestamp":1633595876000},"page":"7332-7340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of Mycobacterium bovis Calmette et Gu\u00e9rin (BCG) in oncotherapy: Bladder cancer and beyond"],"prefix":"10.1016","volume":"39","author":[{"given":"Neelam","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-3978","authenticated-orcid":false,"given":"Esther","family":"Juli\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-5941","authenticated-orcid":false,"given":"Jordi B.","family":"Torrelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.09.053_b0005","series-title":"La vaccination pr\u00e9ventive contre la tuberculose par le \u201cBCG.\u201d","author":"Calmette","year":"1927"},{"issue":"3963","key":"10.1016\/j.vaccine.2021.09.053_b0010","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.170.3963.1217","article-title":"Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG)","volume":"170","author":"Zbar","year":"1970","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/oxfordjournals.aje.a121646","article-title":"Cancer and Tuberculosis","volume":"9","author":"Pearl","year":"1929","journal-title":"Am J Epidemiol"},{"issue":"938","key":"10.1016\/j.vaccine.2021.09.053_b0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/postgradmedj\/79.938.672","article-title":"Dr William Coley and tumour regression: a place in history or in the future","volume":"79","author":"Hoption Cann","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.vaccine.2021.09.053_b0025","doi-asserted-by":"crossref","unstructured":"I H. Employment of B. C. G. especially in Intravenous Injection. Acta Medica Scandinavica 1936;90:350\u201361.","DOI":"10.1111\/j.0954-6820.1936.tb15958.x"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2021.09.053_b0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.09.053_b0035","first-page":"107","article-title":"BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy","volume":"39","author":"Mathe","year":"1973","journal-title":"Natl Cancer Inst Monogr"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0045","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/1097-0142(197511)36:5<1662::AID-CNCR2820360520>3.0.CO;2-6","article-title":"Successful transurethral intralesional BCG therapy of a bladder melanoma","volume":"36","author":"deKernion","year":"1975","journal-title":"Cancer"},{"issue":"2S","key":"10.1016\/j.vaccine.2021.09.053_b0050","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors","volume":"197","author":"Morales","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(17)52736-6","article-title":"Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"128","author":"Brosman","year":"1982","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0065","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","article-title":"Role of urothelial cells in BCG immunotherapy for superficial bladder cancer","volume":"91","author":"Bevers","year":"2004","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","article-title":"Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity","volume":"86","author":"Zhao","year":"2000","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.053_b0080","first-page":"1762","article-title":"Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00299721","article-title":"Morphological aspects of the interaction of Bacillus Calmette-Guerin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?","volume":"20","author":"Teppema","year":"1992","journal-title":"Urol Res"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000474631","article-title":"Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group","volume":"23","author":"Witjes","year":"1993","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0100","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.urology.2012.09.065","article-title":"The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer","volume":"81","author":"Lipsky","year":"2013","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0105","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","volume":"278","author":"Lewis","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/srep27232","article-title":"Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment","volume":"6","author":"Noguera-Ortega","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0115","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-12-1882","article-title":"Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells","volume":"73","author":"Redelman-Sidi","year":"2013","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.053_b0120","doi-asserted-by":"crossref","first-page":"e1004485","DOI":"10.1371\/journal.ppat.1004485","article-title":"Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer","volume":"10","author":"Buffen","year":"2014","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0125","first-page":"181","article-title":"BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines","volume":"9","author":"Bevers","year":"1998","journal-title":"Eur Cytokine Netw"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0140","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.053_b0145","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","article-title":"Intravesical BCG Induces CD4(+) T-Cell Expansion in an Immune Competent Model of Bladder Cancer","volume":"5","author":"Kates","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"31","key":"10.1016\/j.vaccine.2021.09.053_b0150","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"10.1016\/j.vaccine.2021.09.053_b0160","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"issue":"4 Part 1","key":"10.1016\/j.vaccine.2021.09.053_b0165","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","article-title":"Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation","volume":"172","author":"Suttmann","year":"2004","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0170","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0022-5347(17)45922-2","article-title":"Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer","volume":"135","author":"Lage","year":"1986","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0180","doi-asserted-by":"crossref","first-page":"e1293212","DOI":"10.1080\/2162402X.2017.1293212","article-title":"Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes","volume":"6","author":"Garc\u00eda-Cuesta","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0185","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/eji.201040773","article-title":"IL-17 production by gammadelta T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer","volume":"41","author":"Takeuchi","year":"2011","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0190","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against COVID-19?","volume":"20","author":"O'Neill","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.chom.2011.04.006","article-title":"Trained immunity: a memory for innate host defense","volume":"9","author":"Netea","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1590\/S0034-89101992000400004","article-title":"Risk factors for death caused by pneumonia in children younger than 1 year old in a metropolitan region of southeastern Brazil. A case- control study","volume":"26","author":"Niobey","year":"1992","journal-title":"Rev Saude Publica"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0205","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/ije\/20.2.474","article-title":"Childhood mortality among users and non-users of primary health care in a rural west African community","volume":"20","author":"Velema","year":"1991","journal-title":"Int J Epidemiol"},{"issue":"7478","key":"10.1016\/j.vaccine.2021.09.053_b0210","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.38261.496366.82","article-title":"Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso","volume":"329","author":"Vaugelade","year":"2004","journal-title":"BMJ"},{"issue":"7274","key":"10.1016\/j.vaccine.2021.09.053_b0215","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1136\/bmj.321.7274.1435","article-title":"Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa","volume":"321","author":"Kristensen","year":"2000","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.053_b0220","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","article-title":"Non-specific effects of BCG vaccine on viral infections","volume":"25","author":"Moorlag","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"43","key":"10.1016\/j.vaccine.2021.09.053_b0225","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"137","key":"10.1016\/j.vaccine.2021.09.053_b0230","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0235","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and Update for S1602 \u201cA Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle-invasive Bladder Cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.053_b0240","doi-asserted-by":"crossref","first-page":"e1614857","DOI":"10.1080\/2162402X.2019.1614857","article-title":"Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial","volume":"8","author":"Ji","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.vaccine.2021.09.053_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.10.005","article-title":"Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy","volume":"36","author":"Niwa","year":"2018","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2021.09.053_b0255","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1574-6968.2010.01947.x","article-title":"Biochemical characteristics among Mycobacterium bovis BCG substrains","volume":"306","author":"Hayashi","year":"2010","journal-title":"FEMS Microbiol Lett"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: a Systematic Review and Network Meta-Analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2021.09.053_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.622995","article-title":"Natural killer anti-tumor activity can be achieved by in vitro incubation with heat-killed BCG","volume":"12","author":"Esteso","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.053_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Guerin (BCG) Therapy for Bladder Cancer: An Update","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"Immunotargets Ther"},{"issue":"39","key":"10.1016\/j.vaccine.2021.09.053_b0280","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1016\/j.vaccine.2015.08.033","article-title":"Prospects in Mycobacterium bovis Bacille Calmette et Guerin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?","volume":"33","author":"Moliva","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0290","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.053_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.vaccine.2021.09.053_b0305","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.juro.2016.12.024","article-title":"Bacillus Calmette-Guerin Manufacturing and SWOG S1602 Intergroup Clinical Trial","volume":"197","author":"Meeks","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MOU.0000000000000595","article-title":"Bacillus Calmette-Guerin treatment of bladder cancer: a systematic review and commentary on recent publications","volume":"29","author":"Mukherjee","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"Shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guerin Connaught Strain for Bladder Cancer Patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"15","key":"10.1016\/j.vaccine.2021.09.053_b0325","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.02.010","article-title":"Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer","volume":"32","author":"Lamm","year":"2014","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0335","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2021.09.053_b0340","first-page":"112","article-title":"Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.053_b0345","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/CJI.0000000000000130","article-title":"Innovation in bladder cancer immunotherapy","volume":"39","author":"Grossman","year":"2016","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0350","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0355","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients","volume":"23","author":"Derr\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2021.09.053_b0360","doi-asserted-by":"crossref","unstructured":"Juli\u00e1n EN-OaE. Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers. Mycobacterium - Research and Development; 2016. doi: 10.5772\/intechopen.69659.","DOI":"10.5772\/intechopen.69659"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0365","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.4238\/2015.April.15.7","article-title":"Construction of recombinant human IFNalpha-2b BCG and its antitumor effects on bladder cancer cells in vitro","volume":"14","author":"Sun","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.vaccine.2021.09.053_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01460","article-title":"In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.09.053_b0375","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1007\/s00253-015-6495-3","article-title":"Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer","volume":"99","author":"Begnini","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2021.09.053_b0380","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.intimp.2016.03.007","article-title":"Antitumor activity of recombinant Bacille Calmette-Guerin secreting interleukin-15-Ag85B fusion protein against bladder cancer","volume":"35","author":"Takeuchi","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.053_b0385","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.053_b0390","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0395","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.asjsur.2014.01.016","article-title":"Reiter's syndrome postintravesical Bacillus Calmette-Guerin instillations","volume":"40","author":"Ng","year":"2017","journal-title":"Asian J Surg"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0400","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bjorl.2015.10.017","article-title":"Bilateral parotid glands infection caused by Calmette-Guerin Bacillus after intravesical therapy for recurrent bladder cancer: a case report","volume":"83","author":"Friedlander","year":"2017","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.vaccine.2021.09.053_b0405","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.avsg.2016.07.094","article-title":"Arteriocutaneous Fistula Associated with Bilateral Femoral Pseudoaneurysms Caused by Bacillus Calmette-Guerin Apropos of a Case and Review of Literature","volume":"39","author":"Torres-Blanco","year":"2017","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0410","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jvs.2017.02.038","article-title":"Psoas abscess after bacille Calmette-Guerin instillations causing iliac artery contained rupture","volume":"66","author":"Leeman","year":"2017","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0415","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s13104-017-2606-9","article-title":"Poncet's disease after the intravesical instillation of Bacillus Calmette-Guerin (BCG): a case report","volume":"10","author":"Sampaio","year":"2017","journal-title":"BMC Res Notes"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0420","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0425","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5507\/bp.2017.008","article-title":"Methylation status as a predictor of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor","volume":"161","author":"Husek","year":"2017","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"36","key":"10.1016\/j.vaccine.2021.09.053_b0430","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012227","article-title":"The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer: A diagnostic meta-analysis and systematic review","volume":"97","author":"Bao","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.053_b0435","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12032-017-1033-z","article-title":"Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"34","author":"Liem","year":"2017","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0440","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0445","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0450","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1055-9965.EPI-18-0893","article-title":"Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer","volume":"28","author":"Salmasi","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.053_b0455","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urolonc.2017.03.010","article-title":"Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer","volume":"35","author":"Malmstrom","year":"2017","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0460","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/JTO.0b013e3181fb4fcc","article-title":"Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study","volume":"6","author":"Yu","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.053_b0465","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/ijc.24636","article-title":"Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review","volume":"125","author":"Liang","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2021.09.053_b0470","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1476-4598-13-210","article-title":"Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-alpha-induced apoptosis","volume":"13","author":"Holla","year":"2014","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.053_b0475","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071802","article-title":"Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers","volume":"12","author":"Noguera-Ortega","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7597","key":"10.1016\/j.vaccine.2021.09.053_b0480","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(69)92648-8","article-title":"Active immunotherapy for acute lymphoblastic leukaemia","volume":"1","author":"Mathe","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.09.053_b0485","first-page":"115","article-title":"Role of Immunomodulation of BCG Therapy on AML Remission","volume":"14","author":"Kennedy","year":"2021","journal-title":"Int Med Case Rep J"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.053_b0490","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1349-7006.2008.00832.x","article-title":"Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors","volume":"99","author":"Murata","year":"2008","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.053_b0495","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00262-003-0498-0","article-title":"WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone","volume":"53","author":"Nakajima","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0500","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin","volume":"5","author":"Grant","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.vaccine.2021.09.053_b0505","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971\u201308971B; Silva Study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.vaccine.2021.09.053_b0510","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejca.2008.06.036","article-title":"Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2\/BCG in responding patients with limited disease small-cell lung cancer","volume":"44","author":"Bottomley","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2021.09.053_b0515","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fimmu.2017.00965","article-title":"Mycobacterium bovis Bacillus Calmette-Guerin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function","volume":"8","author":"Lardone","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0520","first-page":"363","article-title":"Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update","volume":"13","author":"Gianan","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0525","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.intimp.2012.05.003","article-title":"MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice","volume":"13","author":"Yang","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0530","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/eji.200535490","article-title":"Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity","volume":"36","author":"Li","year":"2006","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.053_b0535","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/nat.2014.0509","article-title":"Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration","volume":"25","author":"Kim","year":"2015","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0540","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12026-012-8332-4","article-title":"Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse","volume":"52","author":"He","year":"2012","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0545","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/sji.12074","article-title":"ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi\/IL-21 in a mouse model","volume":"78","author":"He","year":"2013","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0550","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.4049\/jimmunol.1301135","article-title":"Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents","volume":"191","author":"Kuhn","year":"2013","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.053_b0555","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10120-004-0299-y","article-title":"Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer","volume":"7","author":"Popiela","year":"2004","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0560","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pan.2015.04.001","article-title":"Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway","volume":"15","author":"Pei","year":"2015","journal-title":"Pancreatology"},{"issue":"9","key":"10.1016\/j.vaccine.2021.09.053_b0565","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00432-010-0787-x","article-title":"Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice","volume":"136","author":"Yuan","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.053_b0570","first-page":"1280","article-title":"Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine","volume":"63","author":"Chung","year":"2003","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0575","first-page":"607","article-title":"A novel Bacillus Calmette-Guerin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth","volume":"24","author":"Yuan","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0580","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/07357909509094460","article-title":"Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell\/BCG immunotherapy","volume":"13","author":"Wiseman","year":"1995","journal-title":"Cancer Invest"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.053_b0585","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s12094-015-1320-0","article-title":"Autologous tumor lysate\/Bacillus Calmette-Guerin immunotherapy as an adjuvant to conventional breast cancer therapy","volume":"17","author":"Convit","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.vaccine.2021.09.053_b0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2867-9-30","article-title":"Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Tokyo","volume":"9","author":"Kitamura","year":"2009","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0595","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","article-title":"Mifamurtide: a review of its use in the treatment of osteosarcoma","volume":"12","author":"Frampton","year":"2010","journal-title":"Paediatr Drugs"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.053_b0600","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.053_b0605","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.053_b0610","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","article-title":"IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer","volume":"127","author":"Riemensberger","year":"2002","journal-title":"Clin Exp Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:10Z","timestamp":1759403170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":122,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21012561"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Mycobacterium bovis Calmette et Gu\u00e9rin (BCG) in oncotherapy: Bladder cancer and beyond","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}